ORKA
Price
$101.48
Change
+$1.93 (+1.94%)
Updated
Nov 4, 04:59 PM (EDT)
Capitalization
6.59B
7 days until earnings call
Intraday BUY SELL Signals
SYRE
Price
$99.31
Change
+$0.04 (+0.04%)
Updated
Nov 4, 04:59 PM (EDT)
Capitalization
8.75B
120 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ORKA vs SYRE

ORKA vs SYRE Comparison Chart in %
View a ticker or compare two or three
VS
ORKA vs. SYRE commentary
Nov 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORKA is a StrongBuy and SYRE is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ORKA with price predictions
Nov 03, 2026

ORKA in +0.94% Uptrend, rising for three consecutive days on October 30, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ORKA advanced for three days, in 203 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on ORKA as a result. In 67 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.

The Moving Average Convergence Divergence (MACD) for ORKA just turned positive on October 21, 2026. Looking at past instances where ORKA's MACD turned positive, the stock continued to rise in 39 of 54 cases over the following month. The odds of a continued upward trend are 72%.

ORKA moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ORKA crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORKA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

ORKA broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ORKA entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.929) is normal, around the industry mean (3.051). P/E Ratio (-48.799) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ORKA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORKA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for SYRE with price predictions
Nov 03, 2026

SYRE's Stochastic Oscillator sits in overbought zone for 9 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for SYRE moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for SYRE entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SYRE as a result. In 63 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on October 20, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.

SYRE moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SYRE crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

Following a +7.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 259 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

SYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.168) is normal, around the industry mean (3.051). P/E Ratio (-51.720) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ORKA vs SYRE: Fundamental Ratings
ORKA
SYRE
OUTLOOK RATING
1..100
3381
VALUATION
overvalued / fair valued / undervalued
1..100
4
Undervalued
6
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9496
PRICE GROWTH RATING
1..100
3535
P/E GROWTH RATING
1..100
5850
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORKA's Valuation (4) in the null industry is in the same range as SYRE (6) in the Pharmaceuticals Major industry. This means that ORKA’s stock grew similarly to SYRE’s over the last 12 months.

ORKA's Profit vs Risk Rating (100) in the null industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that ORKA’s stock grew similarly to SYRE’s over the last 12 months.

ORKA's SMR Rating (94) in the null industry is in the same range as SYRE (96) in the Pharmaceuticals Major industry. This means that ORKA’s stock grew similarly to SYRE’s over the last 12 months.

ORKA's Price Growth Rating (35) in the null industry is in the same range as SYRE (35) in the Pharmaceuticals Major industry. This means that ORKA’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (50) in the Pharmaceuticals Major industry is in the same range as ORKA (58) in the null industry. This means that SYRE’s stock grew similarly to ORKA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORKASYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 8 days ago
87%
Declines
ODDS (%)
Bearish Trend 20 days ago
74%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 3 days ago
90%
COMPARISON
Comparison
Nov 04, 2026
Stock price -- (ORKA: $99.55 vs. SYRE: $99.27)
Brand notoriety: ORKA and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ORKA: 85% vs. SYRE: 63%
Market capitalization -- ORKA: $6.59B vs. SYRE: $8.75B
ORKA [@Biotechnology] is valued at $6.59B. SYRE’s [@Biotechnology] market capitalization is $8.75B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $134.53B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORKA’s FA Score shows that 1 FA rating(s) are green while SYRE’s FA Score has 1 green FA rating(s).

  • ORKA’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 1 green, 4 red.
According to our system of comparison, SYRE is a better buy in the long-term than ORKA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORKA’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).

  • ORKA’s TA Score: 5 bullish, 5 bearish.
  • SYRE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than ORKA.

Price Growth

ORKA (@Biotechnology) experienced а +3.90% price change this week, while SYRE (@Biotechnology) price change was +0.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.31%. For the same industry, the average monthly price growth was -10.93%, and the average quarterly price growth was -16.13%.

Reported Earning Dates

ORKA is expected to report earnings on Nov 11, 2026.

SYRE is expected to report earnings on Mar 04, 2027.

Industries' Descriptions

@Biotechnology (-3.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
COYY12.490.06
+0.52%
GraniteShares YieldBOOST COIN ETF (COYY)
IWV428.451.46
+0.34%
iShares Russell 3000 ETF (IWV)
TRND36.050.07
+0.20%
Pacer Trendpilot Fund of Funds ETF (TRND)
DBND43.96-0.06
-0.14%
DoubleLine Opportunistic Core Bond ETF (DBND)
DJIA22.36-0.14
-0.62%
Global X Dow 30 Covered Call ETF (DJIA)